Advertisement

Neuropraxis

, Volume 22, Issue 5, pp 147–153 | Cite as

Het verband tussen cognitieve functies en vasculaire risicofactoren van jongmiddelbare tot oudere leeftijd

  • Marlise E. A. van Eersel
  • Hanneke Joosten
  • Joris P. J. Slaets
  • Gerbrand J. Izaks
Artikel
  • 58 Downloads

Samenvatting

Er is nog geen behandeling om mensen te genezen van dementie. Daarom wordt er veel onderzoek gedaan naar mogelijkheden om dementie te voorkomen. Een van de aandachtspunten binnen het preventieve onderzoek is de behandeling van vasculaire risicofactoren, zoals hypertensie, hypercholesterolemie en diabetes mellitus, en het stoppen met roken. Deze vasculaire risicofactoren veroorzaken aderverkalking, wat bijdraagt aan neurodegeneratieve veranderingen die ten grondslag liggen aan dementie. Het algemene doel van ons onderzoek was om het verband tussen cognitieve functies en vasculaire risicofactoren vanaf jongmiddelbare tot oudere leeftijd te onderzoeken. Daarnaast onderzochten we of er een verband bestaat tussen de verandering in cognitieve functies en de medicamenteuze behandeling van vasculaire risicofactoren. Samenvattend hebben we gevonden dat er een negatief verband is tussen de cognitieve functies en de vasculaire risicofactoren. Hoe hoger het vasculair risico, hoe slechter de cognitieve functies. Dit verband is het sterkst aanwezig op jongmiddelbare leeftijd. Dit suggereert dat er zo vroeg mogelijk gestart zou moeten worden met behandeling van vasculaire risicofactoren om effectief te zijn in het voorkomen van achteruitgang van de cognitieve functies. In dit onderzoek kon echter niet worden bevestigd dat vroege medicamenteuze behandeling van vasculaire risicofactoren de cognitieve functies verbetert.

Trefwoorden

cognitieve functies vasculaire risicofactoren medicamenteuze behandeling van vasculaire risicofactoren 

Literatuur

  1. 1.
    Alzheimer’s Disease International. World Alzheimer report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. Londen: Alzheimer’s Disease International; 2015.Google Scholar
  2. 2.
    World Health Organization. Dementia: a public health priority. 2012. http://apps.who.int/iris/bitstream/10665/75263/1/9789241564458_eng.pdf?ua=1. Geraadpleegd op: 16 mei 2018.Google Scholar
  3. 3.
    Qiu C, Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol. 2015;12(5):267–77.CrossRefGoogle Scholar
  4. 4.
    Rodrigue KM, Rieck JR, Kennedy KM, Devous MDS, Diaz-Arrastia R, Park DC. Risk factors for beta-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol. 2013;70(5):600–6.CrossRefGoogle Scholar
  5. 5.
    Swan GE, Lessov-Schlaggar CN. The effects of tobacco smoke and nicotine on cognition and the brain. Neuropsychol Rev. 2007;17(3):259–73.CrossRefGoogle Scholar
  6. 6.
    Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460–9.CrossRefGoogle Scholar
  7. 7.
    Duron E, Hanon O. Hypertension, cognitive decline and dementia. Arch Cardiovasc Dis. 2008;101(3):181–9.CrossRefGoogle Scholar
  8. 8.
    Berg E van den, Kloppenborg RP, Kessels RP, Kappelle LJ, Biessels GJ. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim Biophys Acta. 2009;1792(5):470–81.CrossRefGoogle Scholar
  9. 9.
    Ligthart SA, Moll van Charante EP, Gool WA Van, Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc Health Risk Manag. 2010;6:775–85.CrossRefGoogle Scholar
  10. 10.
    Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92.CrossRefGoogle Scholar
  11. 11.
    Eersel MEA van. The association of cognitive performance with vascular risk factors across the adult life span. Groningen: Rijksuniversiteit Groningen; 2018.Google Scholar
  12. 12.
    Mahmoodi BK, Gansevoort RT, Veeger NJ, Matthews AG, Navis G, Hillege HL, et al. Microalbuminuria and risk of venous thromboembolism. JAMA. 2009;301(17):1790–7.CrossRefGoogle Scholar
  13. 13.
    Lambers Heerspink HJ, Brantsma AH, Zeeuw D de, Bakker SJ, Jong PE de, Gansevoort RT, et al. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol. 2008;168(8):897–905.CrossRefGoogle Scholar
  14. 14.
    Ruff R. Ruff Figural Fluency Test: professional manual. Lutz: Psychological Assessment Resources; 1996.Google Scholar
  15. 15.
    Lindeboom J, Schmand B. Visual Association Test. Manual. Leiden: PITS BV; 2003.Google Scholar
  16. 16.
    Ruff R, Light R, Evans R. The Ruff Figural Fluency Test: a normative study with adults. Dev Neuropsychol. 1987;3:37–51.CrossRefGoogle Scholar
  17. 17.
    Izaks GJ, Joosten H, Koerts J, Gansevoort RT, Slaets JP. Reference data for the Ruff Figural Fluency Test stratified by age and educational level. PLoS ONE. 2011;6(2):e17045.CrossRefGoogle Scholar
  18. 18.
    D’Agostino RBS, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–53.CrossRefGoogle Scholar
  19. 19.
    Lloyd-Jones DM, Leip EP, Larson MG, D’Agostino RB, Beiser A, Wilson PW, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113(6):791–8.CrossRefGoogle Scholar
  20. 20.
    Visser ST, Schuiling-Veninga CC, Bos JH, de Jong-van den Berg LT, Postma MJ. The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges. Expert Rev Pharmacoecon Outcomes Res. 2013;13(3):285–92.CrossRefGoogle Scholar
  21. 21.
    Joosten H, Eersel ME van, Gansevoort RT, Bilo HJ, Slaets JP, Izaks GJ. Cardiovascular risk profile and cognitive function in young, middle-aged, and elderly subjects. Stroke. 2013;44(6):1543–9.CrossRefGoogle Scholar
  22. 22.
    Eersel ME van, Joosten H, Gansevoort RT, Dullaart RP, Slaets JP, Izaks GJ. The interaction of age and type 2 diabetes on executive function and memory in persons aged 35 years or older. PLoS ONE. 2013;8(12):e82991.CrossRefGoogle Scholar
  23. 23.
    Wu YT, Fratiglioni L, Matthews FE, Lobo A, Breteler MM, Skoog I, et al. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol. 2016;15(1):116–24.CrossRefGoogle Scholar
  24. 24.
    Muller M, Sigurdsson S, Kjartansson O, Jonsson PV, Garcia M, Bonsdorff MB von, et al. Birth size and brain function 75 years later. Pediatrics. 2014;134(4):761–70.CrossRefGoogle Scholar
  25. 25.
    Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291(21):2616–22.CrossRefGoogle Scholar
  26. 26.
    Denton FT, Spencer BG. Chronic health conditions: changing prevalence in an aging population and some implications for the delivery of health care services. Can J Aging. 2010;29(1):11–21.CrossRefGoogle Scholar
  27. 27.
    Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med. 2007;120(3 Suppl 1):S12–S8.CrossRefGoogle Scholar
  28. 28.
    Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care. 1992;15(7):815–9.CrossRefGoogle Scholar
  29. 29.
    Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570–81.CrossRefGoogle Scholar
  30. 30.
    Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. 2000;23(11):542–9.CrossRefGoogle Scholar
  31. 31.
    Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer’s disease. J Alzheimers Dis. 2009;16(4):741–61.CrossRefGoogle Scholar
  32. 32.
    Dickstein DL, Kabaso D, Rocher AB, Luebke JI, Wearne SL, Hof PR. Changes in the structural complexity of the aged brain. Aging Cell. 2007;6(3):275–84.CrossRefGoogle Scholar
  33. 33.
    Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689–701.CrossRefGoogle Scholar
  34. 34.
    Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4(8):487–99.CrossRefGoogle Scholar
  35. 35.
    Tolppanen AM, Solomon A, Soininen H, Kivipelto M. Midlife vascular risk factors and Alzheimer’s disease: evidence from epidemiological studies. J Alzheimers Dis. 2012;32(3):531–40.CrossRefGoogle Scholar
  36. 36.
    Richard E, Andrieu S, Solomon A, Mangialasche F, Ahtiluoto S, Moll van Charante EP, et al. Methodological challenges in designing dementia prevention trials—the European Dementia Prevention Initiative (EDPI). J Neurol Sci. 2012;322(1–2):64–70.CrossRefGoogle Scholar
  37. 37.
    Andrieu S, Coley N, Aisen P, Carrillo MC, DeKosky S, Durga J, et al. Methodological issues in primary prevention trials for neurodegenerative dementia. J Alzheimers Dis. 2009;16(2):235–70.CrossRefGoogle Scholar
  38. 38.
    Euser SM, Bemmel T van, Schram MT, Gussekloo J, Hofman A, Westendorp RGJ, et al. The effect of age on the association between blood pressure and cognitive function later in life. J Am Geriatr Soc. 2009;57(7):1232–7.CrossRefGoogle Scholar
  39. 39.
    Nilsson SE, Read S, Berg S, Johansson B, Melander A, Lindblad U. Low systolic blood pressure is associated with impaired cognitive function in the oldest old: longitudinal observations in a population-based sample 80 years and older. Aging Clin Exp Res. 2007;19(1):41–7.CrossRefGoogle Scholar
  40. 40.
    Zorginstituut Nederland. Farmacotherapeutisch Kompas. 2017. www.farmacotherapeutischkompas.nl. Geraadpleegd op: 16 mei 2018.Google Scholar
  41. 41.
    Strozyk D, Dickson DW, Lipton RB, Katz M, Derby CA, Lee S, et al. Contribution of vascular pathology to the clinical expression of dementia. Neurobiol Aging. 2010;31(10):1710–20.CrossRefGoogle Scholar
  42. 42.
    Bu G. Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10(5):333–44.CrossRefGoogle Scholar

Copyright information

© Bohn Stafleu van Loghum is een imprint van Springer Media B.V., onderdeel van Springer Nature 2018

Authors and Affiliations

  • Marlise E. A. van Eersel
    • 1
  • Hanneke Joosten
    • 2
  • Joris P. J. Slaets
    • 1
  • Gerbrand J. Izaks
    • 1
  1. 1.Universitair Medisch Centrum Groningen, Universitair Centrum OuderengeneeskundeRijksuniversiteit GroningenGroningenNederland
  2. 2.Afdeling Interne Geneeskunde, onderafdeling OuderengeneeskundeMaastricht Universitair Medisch CentrumMaastrichtNederland

Personalised recommendations